.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
AstraZeneca
McKinsey
Accenture
Fuji
Medtronic
Chubb
Johnson and Johnson
Citi
Baxter

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,899,699

« Back to Dashboard

Which drugs does patent 6,899,699 protect, and when does it expire?


Patent 6,899,699 protects NORDITROPIN FLEXPRO, LEVEMIR FLEXTOUCH, NOVOLOG FLEXTOUCH, FIASP FLEXTOUCH, RYZODEG 70/30, SAXENDA, TRESIBA, and XULTOPHY 100/3.6, and is included in eight NDAs.

This patent has eleven patent family members in nine countries.

Summary for Patent: 6,899,699

Title: Automatic injection device with reset feature
Abstract:The present invention relates to a dose setting and expelling device comprising a drive member and a dose setting mechanism which simultaneously sets a given dose and stores the energy necessary for a subsequently driving the drive member in order to expel a dose of medicine from an injection device. According to the invention the dose setting mechanism allows adjustment in both directions, such that a given set dose can be reduced or cancelled by reversing the input motion, typically by rotating a setting member backwardly, this in contrast to the known devices which either requires an additional release mechanism or which cannot be reversed at all.
Inventor(s): Enggaard; Christian (Hiller.o slashed.d, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:10/038,781
Patent Claim Types:
see list of patent claims
Device; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-008Mar 1, 2010BXRXNoNo► Subscribe► Subscribe► SubscribeY
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-009Mar 1, 2010BXRXNoNo► Subscribe► Subscribe► SubscribeY
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-010Mar 1, 2010RXNoNo► Subscribe► Subscribe► SubscribeY
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-011Jan 23, 2015RXNoNo► Subscribe► Subscribe► SubscribeY
Novo Nordisk IncLEVEMIR FLEXTOUCHinsulin detemir recombinantINJECTABLE;SUBCUTANEOUS021536-005Oct 31, 2013RXYesYes► Subscribe► Subscribe► SubscribeY
Novo Nordisk IncNOVOLOG FLEXTOUCHinsulin aspart recombinantINJECTABLE;SUBCUTANEOUS020986-005Oct 31, 2013RXYesYes► Subscribe► Subscribe► SubscribeY
Novo Nordisk IncFIASP FLEXTOUCHinsulin aspart recombinantSOLUTION;SUBCUTANEOUS208751-002Sep 29, 2017RXYesYes► Subscribe► Subscribe► SubscribeY
Novo Nordisk IncRYZODEG 70/30insulin aspart; insulin degludecSOLUTION;SUBCUTANEOUS203313-001Sep 25, 2015RXYesYes► Subscribe► Subscribe► SubscribeY
Novo Nordisk IncSAXENDAliraglutide recombinantSOLUTION;SUBCUTANEOUS206321-001Dec 23, 2014RXYesYes► Subscribe► Subscribe► SubscribeY
Novo Nordisk IncTRESIBAinsulin degludecSOLUTION;SUBCUTANEOUS203314-001Sep 25, 2015RXYesNo► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,899,699

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark2001 00018Jan 05, 2001

Non-Orange Book Patents for Patent: 6,899,699

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,672,898Automatic injection device with reset feature► Subscribe
9,486,588Automatic injection device with reset feature► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,899,699

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan2010188167► Subscribe
Japan2004516895► Subscribe
Japan4643122► Subscribe
Spain2243721► Subscribe
European Patent Office1351732► Subscribe
Germany60204422► Subscribe
Denmark1351732► Subscribe
Japan5431241► Subscribe
Portugal1351732► Subscribe
China1509193► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
US Army
Mallinckrodt
Johnson and Johnson
Baxter
Healthtrust
AstraZeneca
Daiichi Sankyo
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot